
Grace Therapeutics’ Game-Changing GTx-104: Pivotal Phase 3 STRIVE-ON Safety Trial Results Unveiled with a Side of Quirky Optimism
Grace Therapeutics’ GTx-194 Shines in Phase 3 Trials: A Game-Changer for Aneurysmal Subarachnoid Hemorrhage Patients In a groundbreaking announcement, Grace Therapeutics, a pioneering biopharma company, revealed that its Phase 3 STRIVE-ON trial for GTx-104, an innovative intravenous (IV) formulation of nimodipine, has surpassed expectations. This clinical trial, designed to address the significant unmet medical needs…